Recurrent ECSIT mutation encoding V140A triggers hyperinflammation and promotes hemophagocytic syndrome in extranodal NK/T cell lymphoma
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Recurrent ECSIT mutation encoding V140A triggers hyperinflammation and promotes hemophagocytic syndrome in extranodal NK/T cell lymphoma
Authors
Keywords
-
Journal
NATURE MEDICINE
Volume 24, Issue 2, Pages 154-164
Publisher
Springer Nature
Online
2018-01-02
DOI
10.1038/nm.4456
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network
- (2017) Camille Laurent et al. JOURNAL OF CLINICAL ONCOLOGY
- FrequentBCORaberrations in extranodal NK/T-Cell lymphoma, nasal type
- (2016) Akito Dobashi et al. GENES CHROMOSOMES & CANCER
- Exome sequencing identifies somatic mutations of DDX3X in natural killer/T-cell lymphoma
- (2015) Lu Jiang et al. NATURE GENETICS
- Changes in the proteomic profile during the differential polarization status of the human monocyte-derived macrophage THP-1 cell line
- (2015) Fan Zhang et al. PROTEOMICS
- Activating mutations of STAT5B and STAT3 in lymphomas derived from γδ-T or NK cells
- (2015) Can Küçük et al. Nature Communications
- Risk factor analysis of non-Hodgkin lymphoma-associated haemophagocytic syndromes: a multicentre study
- (2014) Hirozumi Sano et al. BRITISH JOURNAL OF HAEMATOLOGY
- CRISPR/Cas-mediated genome editing in the rat via direct injection of one-cell embryos
- (2014) Yanjiao Shao et al. Nature Protocols
- X-ray holography with a customizable reference
- (2014) Andrew V. Martin et al. Nature Communications
- JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer cell lymphoma
- (2013) A Bouchekioua et al. LEUKEMIA
- Clinical features and treatment of natural killer/T cell lymphoma associated with hemophagocytic syndrome: comparison with other T cell lymphoma associated with hemophagocytic syndrome
- (2013) Lijuan Han et al. LEUKEMIA & LYMPHOMA
- Heritable gene targeting in the mouse and rat using a CRISPR-Cas system
- (2013) Dali Li et al. NATURE BIOTECHNOLOGY
- Towards Alzheimer's root cause: ECSIT as an integrating hub between oxidative stress, inflammation and mitochondrial dysfunction
- (2012) Montserrat Soler-López et al. BIOESSAYS
- Complexome Profiling Identifies TMEM126B as a Component of the Mitochondrial Complex I Assembly Complex
- (2012) Heinrich Heide et al. Cell Metabolism
- M-CSF induces the expression of a membrane-bound form of IL-18 in a subset of human monocytes differentiating in vitro toward macrophages
- (2012) Francesca Bellora et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Janus Kinase 3–Activating Mutations Identified in Natural Killer/T-cell Lymphoma
- (2012) Ghee Chong Koo et al. Cancer Discovery
- Long-term outcomes of patients with newly diagnosed extranodal natural killer/T-cell lymphoma treated by etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin regimen: a single-institution experience
- (2011) Huiqiang Huang et al. LEUKEMIA & LYMPHOMA
- Crosstalk in NF-κB signaling pathways
- (2011) Andrea Oeckinghaus et al. NATURE IMMUNOLOGY
- Immunity, Inflammation, and Cancer
- (2010) Sergei I. Grivennikov et al. CELL
- Regulation and Function of NF-κB Transcription Factors in the Immune System
- (2009) Sivakumar Vallabhapurapu et al. Annual Review of Immunology
- Histiocytic Disorders: Recent Insights into Pathophysiology and Practical Guidelines
- (2009) Alexandra Filipovich et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Thalidomide for treatment of multiple myeloma: 10 years later
- (2008) A. Palumbo et al. BLOOD
- International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes
- (2008) JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started